Efficacy of a low dose of thalidomide in advanced multiple myeloma [11]

Blood

Volumn 100, Issue 4, 2002, Pages 1519-1520

  Leleu, Xavier ^a   Magro, Leonardo ^a   Fawaz, Abir ^a   Bauters, Francis ^a   Facon, Tierry ^a   Yakoub Agha, Ibrahim ^a  

^a CHU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; MELPHALAN; THALIDOMIDE;

ADULT; ADVANCED CANCER; AGED; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; LETTER; MULTIPLE MYELOMA; NAUSEA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037103198     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-05-1527     Document Type: Letter

References (3)

1. Antitumor activity of thalidomide in refractory multiple myeloma
2. Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM)
3. Thalidomide in patients with advanced myeloma: A study of 83 patients-report of the Intergroupe Francophone du Myelome (IFM)